International Circuit
H2-Pharma And CHEPLAPHARM Announce Launch of ETOPOPHOS® Injection
H2-Pharma, LLC, a privately held pharmaceutical company, announced today that it has entered into an agreement with CHEPLAPHARM Arzneimittel GmbH to be the exclusive U.S. distributor of ETOPOPHOS® (etoposide phosphate) for injection. This opportunity arose due to its successful partnership with CHEPLAPHARM Arzneimittel GmbH, who has recently completed its acquisition of ETOPOPHOS® from Bristol-Myers Squibb.
ETOPOPHOS®, indicated for the treatment of refractory testicular tumors, in combination with other chemotherapeutic drugs, and small cell lung cancer, in combination with cisplatin, as a first-line treatment, received marketing approval from the U.S. Food and Drug Administration in 1983.
“We have commenced the distribution of ETOPOPHOS®, which represents the second branded product that H2-Pharma has brought to the U.S. market through our partnership with CHEPLAPHARM,” said Brooke Cantey, H2-Pharma’s President. “Continuing the availability of late lifecycle branded products shows our commitment to our patients and customers in keeping important drugs on the market.” – Bio Space